In FRESCO-2, the majority of ARs were manageable and predictable1,3
In FRESCO-2, the most common (≥10% of patients) adverse reactions observed following treatment with FRUZAQLA were:1
bRepresents a composite of multiple related terms.
Predictable refers to ARs consistent with inhibition of VEGF and VEGFR*
Low rate of discontinuations due to ARs: 20% with FRUZAQLA + BSC vs 21% for placebo + BSC
Serious adverse reactions occurred in 38% of patients treated with FRUZAQLA + BSC. Serious adverse reactions in ≥2% of patients treated with FRUZAQLA included hemorrhage (2.2%) and gastrointestinal perforation (2.0%)1
Fatal adverse reaction(s) occurred in 14 (3.1%) patients who received FRUZAQLA. Fatal adverse reactions occurring in ≥2 patients include pneumonia (n=3), sepsis/septic shock (n=2), and hepatic failure/encephalopathy (n=2).1
AR=adverse reaction; BSC=best supportive care; CI=confidence interval; HR=hazard ratio.
*Despite predictability, individual patient experiences may vary.
Convenient, once-daily oral dosing1
Simple dose reductions can be implemented to help manage adverse reactions. The recommended starting dose is 5 mg orally once daily. The first dose reduction is 4 mg orally once daily. The second dose reduction is 3 mg orally once daily. Permanently discontinue FRUZAQLA in patients unable to tolerate 3 mg orally once daily.1
- Continue treatment until disease progression or unacceptable toxicity1
- Do not take an additional dose if vomiting occurs after taking FRUZAQLA, but continue with the next scheduled dose1
Takeda offers a range of resources to help support your patients. Patient assistance can help with coverage, financial assistance, and more.
From helping patients understand coverage options to identifying available financial assistance, Takeda Oncology Here2Assist® is committed to offering your patients comprehensive support.